Common Contracts
2 similar Voting Agreement contracts by FWHC Holdings, LLC, H-Cyte, Inc.
H-CYTE, INC. AMENDED AND RESTATED VOTING AGREEMENT as of November 15, 2019 AMENDED AND RESTATED VOTING AGREEMENTVoting Agreement • February 25th, 2020 • FWHC Holdings, LLC • Surgical & medical instruments & apparatus • Nevada
This Amended and Restated Voting Agreement (this "Agreement") is entered into as of November 15, 2019 by and among (i) H-Cyte, Inc., a Nevada corporation (the "Company"), (ii) each holder of the Company's Series B Preferred Stock ("Series B Preferred Stock") listed on Schedule I (the "Series B Investors"), (iii) each holder of the Company's Series D Preferred Stock ("Series D Preferred Stock") listed on Schedule II (the "Series D Investors" and, together with the Series Series B Investors, and any subsequent investors, or transferees, who become parties hereto as "Investors" pursuant to Sections 6.1(a) or 6.2 below, the "Investors") and (vi) those certain stockholders of the Company listed on Schedule III (together with any subsequent stockholders, or any transferees, who become parties hereto as "Key Holders" pursuant to Sections 6.1(b) or 6.2 below, the "Key Holders," and together collectively with the Investors, the "Stockholders").
H-CYTE, INC. AMENDED AND RESTATED VOTING AGREEMENT as of November 15, 2019 AMENDED AND RESTATED VOTING AGREEMENTVoting Agreement • November 21st, 2019 • H-Cyte, Inc. • Surgical & medical instruments & apparatus • Nevada
This Amended and Restated Voting Agreement (this “Agreement”) is entered into as of November 15, 2019 by and among (i) H-Cyte, Inc., a Nevada corporation (the “Company”), (ii) each holder of the Company’s Series B Preferred Stock (“Series B Preferred Stock”) listed on Schedule I (the “Series B Investors”), (iii) each holder of the Company’s Series D Preferred Stock (“Series D Preferred Stock”) listed on Schedule II (the “Series D Investors” and, together with the Series Series B Investors, and any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Sections 6.1(a) or 6.2 below, the “Investors”) and (vi) those certain stockholders of the Company listed on Schedule III (together with any subsequent stockholders, or any transferees, who become parties hereto as “Key Holders” pursuant to Sections 6.1(b) or 6.2 below, the “Key Holders,” and together collectively with the Investors, the “Stockholders”).
